Antibodies

15 June 2008

New data reveals Actemra is the first and only biologic drug to show superiority over current standard of care in rheumatoid arthritis

15 June 2008

Data from Phase II Exploratory Study Suggest That ORENCIA(R) (abatacept) May Delay Development of Rheumatoid Arthritis in Adults with Undifferentiated Inflammatory Arthritis

15 June 2008

New Long-Term HUMIRA(R) (adalimumab) Data Show Up to Seven-Year Efficacy with Combination Treatment for Rheumatoid Arthritis

15 June 2008

Data Show that Abbott’s HUMIRA(R) (adalimumab) Reduced the Signs and Symptoms of Ankylosing Spondylitis Up to Three Years

15 June 2008

HUMIRA(R) (adalimumab) Data Show That Treating Early Rheumatoid Arthritis with Combination Treatment Resulted in Cost Savings From Improved Work Productivity

12 June 2008

Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia

12 June 2008

ORENCIA(R) (abatacept) Provided an Increasing Degree of Inhibition of Structural Damage Through Three Years in Adults with Moderate to Severe Rheumatoid Arthritis

11 June 2008

Ofatumumab in subcutaneous study in rheumatoid arthritis

11 June 2008

Phase 3 Data Show Efficacy of Golimumab in Patients with Active Rheumatoid Arthritis Previously Treated with Anti-TNF Agents

10 June 2008

Symphogen Enters into strategic collaboration with Genentech for antibody thera-peutics

9 June 2008

Sequential R-CHOP and Ibritumomab Tiuxetan (Zevalin(R)) Regimen Produces Impressive Survival Rates in High Risk Elderly Patients With Untreated Aggressive Diffuse Large B-cell Lymphoma

9 June 2008

XOMA 052 Demonstrates Anti-Inflammatory Effect in Arthritis Animal Studies; Data Presented At FOCIS

8 June 2008

WILEX and IBA enter into worldwide marketing, distribution and sales agreement on REDECTANE(R) (CA9-SCAN)

5 June 2008

Seattle Genetics Reports Final SGN-40 Phase I Non-Hodgkin Lymphoma Data at International Conference on Malignant Lymphoma

5 June 2008

Micromet’s BiTE Antibody Blinatumomab (MT103/MEDI-538) Demonstrates Durable Responses in Patients with Relapsed Non-Hodgkin’s Lymphoma

5 June 2008

Amgen and Wyeth Statement on the FDA Early Communication About Tumor Necrosis Factor (TNF) Blockers

5 June 2008

Merck Announces Initiation of Second Phase II/III Clinical Study of Atacicept in Lupus

4 June 2008

ImmunoGen, Inc. Announces Presentation of Encouraging Clinical Findings with Trastuzumab-DM1 at ASCO

4 June 2008

Seattle Genetics Reports Multiple Complete and Partial Responses with SGN-35 in Patients with Lymphoma

4 June 2008

BioInvent and ThromboGenics report positive Phase I results for anti-PlGF cancer therapeutic TB-403

4 June 2008

Bradmer Receives FDA Approval to Proceed with Phase III Clinical Trial

3 June 2008

Seattle Genetics Announces Initiation of SGN-40 Phase Ib Clinical Trial in Combination With Velcade for Multiple Myeloma

3 June 2008

Trubion Announces Presentation of Positive TRU-016 Data at ASCO

3 June 2008

New Pfizer Data Presented on CP-751,871 across Non-Small Cell Lung Cancer and Ewing’s Sarcoma

3 June 2008

Preliminary Data from Ongoing Phase 1 Data of Investigational Anti-PD-1 Antibody Presented at American Society of Clinical Oncology Annual Meeting

3 June 2008

Interim Phase 1/2 Data of Ipilimumab in Prostate Cancer Presented at American Society of Clinical Oncology Annual Meeting

2 June 2008

Amgen Reports Positive Data at ASCO from Three Studies of Denosumab in Cancer Patients

2 June 2008

Updated Data from Ongoing Phase 3 Trials Support the Continued Study of Vectibix(R) (panitumumab) in Combination with Standard Chemotherapy

2 June 2008

Interim Phase 2 Results of Open-Label Clinical Trial of Denosumab in Giant Cell Tumor of Bone Demonstrated 87 Percent Response Rate

2 June 2008

CuraGen Announces Data From Ongoing Phase I/II Trial Showing Clinical Activity of CR011-vcMMAE in Metastatic Melanoma

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

Antibody Target, Technology & Pipeline Database: 1-Year Subscription

CD38-Targeted Antibody & Cell Therapy Pipeline Review

TSLP Pipeline Review

GPRC5D-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

Intracellular Targets made druggable by TCR-like Antibodies, TCR Fusion Proteins & Cell-Penetrating Biologics 2018: an industry analysis of technologies, stakeholders, deals & trends

Eculizumab (Soliris) Biosimilars & Biosuperiors Pipeline Review

ROR1-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

FcRn Inhibitors Pipeline Review

Bispecific Antibodies for Immuno-Oncology & Other Diseases

CAR-M Industry Landscape Analysis: Chimeric Antigen Receptor-Macrophage (CAR-M) Stakeholders, Technologies, Pipeline, Partnering and Financing